Human immunodeficiency virus-uninfected adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a @ - or @-month moxifloxacin regimen ( moxifloxacin -LSB- M -RSB- , isoniazid -LSB- H -RSB- , rifampicin -LSB- R -RSB- , pyrazinamide -LSB- Z -RSB- , ethambutol -LSB- E -RSB- ) or the control regimen ( RHZE thrice weekly ) .